COMMUNIQUÉS West-GlobeNewswire

Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet
30/06/2026
-- Pacira to receive up to $140 million with $70 million upfront and up to an additional $70 million in potential future revenue-based milestone payments -- -- Two companies will collaborate on advancing the spasticity [...]
Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1
30/06/2026
GeneTAC ® small molecule designed to selectively reduce transcription of the mutant DMPK allele and address the underlying cause of DM1 CARLSBAD, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. ( [...]
TerrAscend Signs Agreement to Acquire Fifth Dispensary in New Jersey
30/06/2026
Aunt Mary’s, a high-performing dispensary in Hunterdon County, generates over $10 million in annualized revenue Transaction expected to be immediately accretive on an EBITDA and free cash flow basis, further extending [...]
SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
30/06/2026
Dose-optimization data from the Phase 1 study expected Q3 2026 to support Phase 2 proof-of-concept initiation in ADPKD in Q4 2026 JERSEY CITY, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX ), a [...]
U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA
30/06/2026
Vafseo ® demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen Primary Investigator to stop trial on recommendation from Independent [...]
InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos
30/06/2026
InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV) The Company is assessing the most efficient development plan to [...]
Flare Therapeutics Secures $85M in Insider-Led Series C Financing and Appoints Anna Protopapas as Chief Executive Officer
30/06/2026
- Proceeds will fund advancement of AR ON degrader, FX-111, to proof of concept and preclinical development of AR ON RIPTAC program - Veteran biotech executive, Anna Protopapas, appointed as CEO to guide company through [...]
Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
30/06/2026
Phase 3 clinical trial will evaluate aglatimagene besadenovec plus valacyclovir in combination with continued pembrolizumab versus standard-of-care docetaxel chemotherapy in patients with metastatic, non-squamous, non- [...]
Provectus Biopharmaceuticals and VisiRose Announce U.S. Patent Award for Light-Independent Antibacterial Eye Drop Targeting Drug-Resistant Ocular Infections
30/06/2026
New IP covers topical rose bengal sodium ophthalmic composition against MRSA and other resistant Gram-positive bacteria without requiring light activation. VisiRose to hold exclusive ophthalmic license. KNOXVILLE, Tenn [...]
NurExone Announces Closing of Non-Brokered Private Placement
30/06/2026
TORONTO, Ontario and HAIFA, Israel, June 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a biopharmaceutical company developing exosome-based [...]
BellaSeno’s regenerative scaffolds signal new era for breast surgery
30/06/2026
MedTech company, BellaSeno, is accelerating human trials of its proprietary breast scaffolds as it moves regenerative breast surgery toward clinical adoption LEIPZIG, Germany and SYDNEY, June 30, 2026 (GLOBE NEWSWIRE [...]
Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control
30/06/2026
Both Annamycin dose arms outperformed control on the primary endpoint of complete remission (CR): 43% and 36% versus 12% — reported on a full intent-to-treat (ITT) basis with no patient exclusions Composite complete [...]
Microbot Medical® Increases Manufacturing Capacity as Demand for the LIBERTY® System Rises; Enters into Strategic Agreement with Sanmina, a Global Manufacturing Leader
30/06/2026
Expanding manufacturing capabilities is part of the Company’s cost reduction strategy and supports global expansion HINGHAM, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and [...]
Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer
30/06/2026
- Findings provide mechanistic support for previously reported clinical outcomes of clinical reversal of platinum resistance/refractoriness from Phase 2 VIRO-15 trial - - Data demonstrate Olvi-Vec–mediated modulation of [...]
Salipro Biotech Announces Publication in Nature Scientific Reports on Expanding DEL Screening to Membrane Proteins
30/06/2026
Study demonstrates application of DNA-Encoded Library screening to native-like membrane protein targets with the Salipro® platform STOCKHOLM, June 30, 2026 (GLOBE NEWSWIRE) -- Salipro Biotech AB today announced the [...]
Zelluna ASA awarded NOK 16 million Research Council of Norway grant
30/06/2026
Oslo, 29 June 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced that the [...]
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
30/06/2026
This marks the fourth R&D milestone achieved under the collaboration, and the second in 2026, reflecting the steady progress of development under the collaboration Under the terms of the agreement, Nxera is eligible [...]
smartbax secures additional financing to advance lead antibiotic program to IND filing
30/06/2026
Munich, Germany, June 30, 2026 (GLOBE NEWSWIRE) -- smartbax, a biotech company developing next-generation antibiotics against multi-drug resistant bacteria, today announced the successful second closing of its Pre- [...]
HUTCHMED to Announce 2026 Half-Year Financial Results
30/06/2026
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM: HCM; HKEX:13) will announce its interim results for the six months ended June 30, [...]

Pages